Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations (STICS)
Primary Purpose
Asthma
Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Fluticasone 44 mcg
Fluticasone 220 mcg
Sponsored by

About this trial
This is an interventional treatment trial for Asthma focused on measuring Asthma, Fluticasone
Eligibility Criteria
Inclusion Criteria:
- Physician-diagnosed asthma
- At least 1 exacerbation treated with systemic (oral or injectable) corticosteroids in the past 12 months
- Able to perform reproducible spirometry
- Current treatment with step 2 controller therapy [low-dose ICS, leukotriene receptor antagonist (LTRA)] OR current treatment with step 3 controller therapy [low-dose ICS + long-acting beta agonist (LABA), low-dose ICS + LTRA, or medium dose ICS] with a childhood Asthma Control Test (c-ACT) score of >19, no more than 2 prednisone treated exacerbations in the past 6 months, prebronchodilator Forced Expiratory Volume at 1 second (FEV1) ≥ 80% predicted and willing to step down therapy OR controller naïve and qualifying for step 2 controller therapy [asthma symptoms or short acting beta agonist (SABA) use > 2 days per week or night-time awakenings due to asthma > 2 nights per month]
- Prebronchodilator FEV1 ≥ 60% predicted
- Ability and willingness to provide informed assent
- For females of childbearing potential: not pregnant, non-lactating, and agree to practice an adequate birth control method.
- History of clinical varicella or varicella vaccine
Exclusion Criteria:
- Systemic (oral or injectable) corticosteroids within previous 2-week period
- Current or recent (previous 2-weeks) use of medications known to significantly interact with corticosteroid disposition, including but not limited to carbamazepine, erythromycin, phenobarbital, phenytoin, rifampin, and ketoconazole
- Presence of chronic or active lung disease other than asthma
- Significant medical illness other than asthma, including thyroid disease, diabetes mellitus, Cushing's disease, Addison's disease, hepatic disease, or concurrent medical problems that could require oral corticosteroids during the study
- A history of cataracts, glaucoma, or any other medical disorder associated with an adverse effect to corticosteroids
- History of a life-threatening asthma exacerbation requiring intubation, mechanical ventilation, or resulting in a hypoxic seizure
- More than 5 prednisone treated exacerbations in the past 12 months
- More than 1 hospitalizations lasting >24 hours for asthma in the past 12 months
- History of adverse reactions to ICS preparations or any of their ingredients
- Receiving hyposensitization therapy other than an established maintenance regimen (On maintenance regimen for ≥ 3 months)
- History of premature birth before 35 weeks gestation
Sites / Locations
- University of Arizona College of Medicine
- Children's Hospital & Research Center Oakland
- UCSF Benioff Children's Hospital
- National Jewish Health
- Nemours Children's Clinic
- Nemours Children's Clinic
- Emory University
- Rush University Medical Center/Stroger Hospital
- University of Illinois at Chicago
- Ann and Robert H. Lurie Children's Hospital
- Children's Hospital Boston
- St. Louis Children's Hospital
- Washington University
- Wake Forest University Health Sciences
- Rainbow Babies and Children's Hospital, Case Western Reserve University
- Allegheny General Hospital
- Children's Hospital of Pittsburgh of UPMC
- University of Wisconsin
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Fluticasone 44 mcg
Fluticasone 220 mcg
Arm Description
Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of "yellow zone" symptoms.
Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of "yellow zone" symptoms.
Outcomes
Primary Outcome Measures
Asthma Exacerbations
The primary outcome is the rate of severe asthma exacerbations treated with oral corticosteroids during the 48 week treatment period.
Secondary Outcome Measures
Yellow Zone Asthma Symptoms
Study participants completed a daily symptom diary. They scored the following diary elements on a scale from 0-3 (none-severe): Cough, Wheeze, Trouble Breathing, Interference With Activities. A combined score was calculated as the sum of the 4 elements and ranged from 0 to 12. The study intervention was based on yellow-zones as noted in the Study Description. This outcome was based on diary data including 21 days, beginning 7 days prior to the onset of the yellow-zone intervention and ending 14 days after the onset of the intervention. The total symptom burden outcome was defined as the sum of the combined score on each diary day and ranged from 0 to 252 (max combined score of 12 per day multiplied by 21 days). A score of zero would indicate no symptoms over the entire 21 days. A score of 252 would indicate severe cough, wheeze, shortness of breath, and interference with activities on all of the 21 days.
Yellow Zone Albuterol Use
Use of albuterol rescue medication during 7-day yellow zone episodes.
Unscheduled Emergency Department (ED) or Urgent Care Visits for Asthma
Rate of emergency department (ED) or urgent care visits for asthma during the 48 week treatment period.
Number of Participants Hospitalized for Asthma
Number of participants hospitalized for asthma during the 48 week treatment period.
Full Information
NCT ID
NCT02066129
First Posted
February 17, 2014
Last Updated
June 11, 2018
Sponsor
Milton S. Hershey Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT02066129
Brief Title
Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations
Acronym
STICS
Official Title
Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations
Study Type
Interventional
2. Study Status
Record Verification Date
June 2018
Overall Recruitment Status
Completed
Study Start Date
July 2014 (undefined)
Primary Completion Date
April 21, 2017 (Actual)
Study Completion Date
April 21, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Milton S. Hershey Medical Center
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The objective of this study is to determine whether, in children receiving low-dose inhaled corticosteroids (ICS), quintupling the dose of inhaled corticosteroids at the onset of symptoms previously associated with upper respiratory illnesses and subsequent asthma exacerbations reduces the rate of severe asthma exacerbations treated with oral corticosteroids.
Detailed Description
The study design is a double-blind, parallel-group trial, including a total of 250 participants, ages 5-11 years, with a diagnosis of asthma and a history of at least 1 asthma exacerbation treated with oral corticosteroids in the prior year. All participants will be treated for 48 weeks with open-label fluticasone 44 mcg 2 puffs twice daily. During the 48-week treatment period, participants will receive randomized blinded therapy for 7 days each time they enter the "yellow zone" (at the onset of symptoms previously associated with upper respiratory illnesses and subsequent asthma exacerbations). Yellow zone therapy will be fluticasone 44 or 220 mcg 2 puffs twice daily.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Asthma, Fluticasone
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
254 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Fluticasone 44 mcg
Arm Type
Active Comparator
Arm Description
Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of "yellow zone" symptoms.
Arm Title
Fluticasone 220 mcg
Arm Type
Active Comparator
Arm Description
Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of "yellow zone" symptoms.
Intervention Type
Drug
Intervention Name(s)
Fluticasone 44 mcg
Other Intervention Name(s)
Flovent® 44 mcg
Intervention Description
Fluticasone is an inhaled corticosteroid
Intervention Type
Drug
Intervention Name(s)
Fluticasone 220 mcg
Other Intervention Name(s)
Flovent® 220 mcg
Intervention Description
Fluticasone is an inhaled corticosteroid
Primary Outcome Measure Information:
Title
Asthma Exacerbations
Description
The primary outcome is the rate of severe asthma exacerbations treated with oral corticosteroids during the 48 week treatment period.
Time Frame
end of 48 week treatment period
Secondary Outcome Measure Information:
Title
Yellow Zone Asthma Symptoms
Description
Study participants completed a daily symptom diary. They scored the following diary elements on a scale from 0-3 (none-severe): Cough, Wheeze, Trouble Breathing, Interference With Activities. A combined score was calculated as the sum of the 4 elements and ranged from 0 to 12. The study intervention was based on yellow-zones as noted in the Study Description. This outcome was based on diary data including 21 days, beginning 7 days prior to the onset of the yellow-zone intervention and ending 14 days after the onset of the intervention. The total symptom burden outcome was defined as the sum of the combined score on each diary day and ranged from 0 to 252 (max combined score of 12 per day multiplied by 21 days). A score of zero would indicate no symptoms over the entire 21 days. A score of 252 would indicate severe cough, wheeze, shortness of breath, and interference with activities on all of the 21 days.
Time Frame
end of 48 week treatment period
Title
Yellow Zone Albuterol Use
Description
Use of albuterol rescue medication during 7-day yellow zone episodes.
Time Frame
end of 48 week treatment period
Title
Unscheduled Emergency Department (ED) or Urgent Care Visits for Asthma
Description
Rate of emergency department (ED) or urgent care visits for asthma during the 48 week treatment period.
Time Frame
end of 48 week treatment period
Title
Number of Participants Hospitalized for Asthma
Description
Number of participants hospitalized for asthma during the 48 week treatment period.
Time Frame
end of 48 week treatment period
10. Eligibility
Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
11 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Physician-diagnosed asthma
At least 1 exacerbation treated with systemic (oral or injectable) corticosteroids in the past 12 months
Able to perform reproducible spirometry
Current treatment with step 2 controller therapy [low-dose ICS, leukotriene receptor antagonist (LTRA)] OR current treatment with step 3 controller therapy [low-dose ICS + long-acting beta agonist (LABA), low-dose ICS + LTRA, or medium dose ICS] with a childhood Asthma Control Test (c-ACT) score of >19, no more than 2 prednisone treated exacerbations in the past 6 months, prebronchodilator Forced Expiratory Volume at 1 second (FEV1) ≥ 80% predicted and willing to step down therapy OR controller naïve and qualifying for step 2 controller therapy [asthma symptoms or short acting beta agonist (SABA) use > 2 days per week or night-time awakenings due to asthma > 2 nights per month]
Prebronchodilator FEV1 ≥ 60% predicted
Ability and willingness to provide informed assent
For females of childbearing potential: not pregnant, non-lactating, and agree to practice an adequate birth control method.
History of clinical varicella or varicella vaccine
Exclusion Criteria:
Systemic (oral or injectable) corticosteroids within previous 2-week period
Current or recent (previous 2-weeks) use of medications known to significantly interact with corticosteroid disposition, including but not limited to carbamazepine, erythromycin, phenobarbital, phenytoin, rifampin, and ketoconazole
Presence of chronic or active lung disease other than asthma
Significant medical illness other than asthma, including thyroid disease, diabetes mellitus, Cushing's disease, Addison's disease, hepatic disease, or concurrent medical problems that could require oral corticosteroids during the study
A history of cataracts, glaucoma, or any other medical disorder associated with an adverse effect to corticosteroids
History of a life-threatening asthma exacerbation requiring intubation, mechanical ventilation, or resulting in a hypoxic seizure
More than 5 prednisone treated exacerbations in the past 12 months
More than 1 hospitalizations lasting >24 hours for asthma in the past 12 months
History of adverse reactions to ICS preparations or any of their ingredients
Receiving hyposensitization therapy other than an established maintenance regimen (On maintenance regimen for ≥ 3 months)
History of premature birth before 35 weeks gestation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
William Busse, MD
Organizational Affiliation
University of Wisconsin, Madison
Official's Role
Study Chair
Facility Information:
Facility Name
University of Arizona College of Medicine
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85724
Country
United States
Facility Name
Children's Hospital & Research Center Oakland
City
Oakland
State/Province
California
ZIP/Postal Code
94609
Country
United States
Facility Name
UCSF Benioff Children's Hospital
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
Facility Name
National Jewish Health
City
Denver
State/Province
Colorado
ZIP/Postal Code
80206
Country
United States
Facility Name
Nemours Children's Clinic
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32207
Country
United States
Facility Name
Nemours Children's Clinic
City
Orlando
State/Province
Florida
ZIP/Postal Code
32827
Country
United States
Facility Name
Emory University
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Facility Name
Rush University Medical Center/Stroger Hospital
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Facility Name
University of Illinois at Chicago
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Facility Name
Ann and Robert H. Lurie Children's Hospital
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60614
Country
United States
Facility Name
Children's Hospital Boston
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
St. Louis Children's Hospital
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Washington University
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Wake Forest University Health Sciences
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States
Facility Name
Rainbow Babies and Children's Hospital, Case Western Reserve University
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Facility Name
Allegheny General Hospital
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15212
Country
United States
Facility Name
Children's Hospital of Pittsburgh of UPMC
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15224
Country
United States
Facility Name
University of Wisconsin
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53972
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
29504498
Citation
Jackson DJ, Bacharier LB, Mauger DT, Boehmer S, Beigelman A, Chmiel JF, Fitzpatrick AM, Gaffin JM, Morgan WJ, Peters SP, Phipatanakul W, Sheehan WJ, Cabana MD, Holguin F, Martinez FD, Pongracic JA, Baxi SN, Benson M, Blake K, Covar R, Gentile DA, Israel E, Krishnan JA, Kumar HV, Lang JE, Lazarus SC, Lima JJ, Long D, Ly N, Marbin J, Moy JN, Myers RE, Olin JT, Raissy HH, Robison RG, Ross K, Sorkness CA, Lemanske RF Jr; National Heart, Lung, and Blood Institute AsthmaNet. Quintupling Inhaled Glucocorticoids to Prevent Childhood Asthma Exacerbations. N Engl J Med. 2018 Mar 8;378(10):891-901. doi: 10.1056/NEJMoa1710988. Epub 2018 Mar 3.
Results Reference
derived
Links:
URL
http://asthmanetresearch.org/
Description
AsthmaNet
Learn more about this trial
Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations
We'll reach out to this number within 24 hrs